PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by 
activation of Akt and EGFR

Sos, Martin; Koker, Mirjam; Weir, Barbara; Heynck, Stefanie; Rabinovsky, Rosalia; Zander, Thomas; Seeger, Jens M.; Weiss, Jonathan; Fischer, Florian; Frommolt, Peter; Michel, Kathrin; Peifer, Martin; Mermel, Craig; Girard, Luc; Peyton, Michael; Gazdar, Adi F.; Minna, John D.; Garraway, Levi A.; Kashkar, Hamid; Pao, William; Meyerson, Matthew; Thomas, Roman K.

Lokale TagsFreigabegeschichteDetailsÜbersicht

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

Sos, M., Koker, M., Weir, B., Heynck, S., Rabinovsky, R., Zander, T., et al. (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research, 69(8), 3256-3261.

Item is Freigegeben

einblenden: alle ausblenden: alle

Basisdaten

einblenden: ausblenden:

Datensatz-Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D892-0 Versions-Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D893-E

Genre: Zeitschriftenartikel

ausblenden:

Urheber:
Sos, Martin¹, Autor
Koker, Mirjam¹, Autor
Weir, Barbara², Autor
Heynck, Stefanie¹, Autor
Rabinovsky, Rosalia², Autor
Zander, Thomas³, Autor
Seeger, Jens M.², Autor
Weiss, Jonathan¹, Autor
Fischer, Florian¹, Autor
Frommolt, Peter², Autor
Michel, Kathrin¹, Autor
Peifer, Martin¹, Autor
Mermel, Craig², Autor
Girard, Luc², Autor
Peyton, Michael², Autor
Gazdar, Adi F.², Autor
Minna, John D.², Autor
Garraway, Levi A.², Autor
Kashkar, Hamid², Autor
Pao, William², Autor
Meyerson, Matthew², AutorThomas, Roman K.¹, Autor          mehr..

Affiliations:
1Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149656
21. Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA 2. Univ Texas SW Med Ctr Dallas, Dept Internal Med & Pharmacol, Dallas, TX 75390 USA 3. Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA 4. Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA 5. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA 6. Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA, ou_persistent22
3Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149663